Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $911000.0.

  • Kezar Life Sciences' Accounts Payables fell 7367.81% to $911000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $911000.0, marking a year-over-year decrease of 7367.81%. This contributed to the annual value of $3.7 million for FY2024, which is 5575.08% down from last year.
  • Latest data reveals that Kezar Life Sciences reported Accounts Payables of $911000.0 as of Q3 2025, which was down 7367.81% from $1.2 million recorded in Q2 2025.
  • Kezar Life Sciences' 5-year Accounts Payables high stood at $8.3 million for Q4 2023, and its period low was $911000.0 during Q3 2025.
  • Moreover, its 5-year median value for Accounts Payables was $2.3 million (2022), whereas its average is $2.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 23283.58% in 2023, then plummeted by 7367.81% in 2025.
  • Kezar Life Sciences' Accounts Payables (Quarter) stood at $2.0 million in 2021, then grew by 22.24% to $2.5 million in 2022, then surged by 232.84% to $8.3 million in 2023, then tumbled by 55.75% to $3.7 million in 2024, then crashed by 75.05% to $911000.0 in 2025.
  • Its Accounts Payables stands at $911000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $2.0 million for Q1 2025.